ImClone to reapply for approval of cancer drug
ImClone Systems Inc. has said that it will reapply in the second half of this year for approval of Erbitux, the cancer drug whose initial rejection by the U.S. Food and Drug Administration sparked
ImClone Systems Inc. has said that it will reapply in the second half of this year for approval of Erbitux, the cancer drug whose initial rejection by the U.S. Food and Drug Administration sparked